Belotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer.
- Author:
Jeong Eun LEE
1
;
Kye Young LEE
;
Hee Sun PARK
;
Sung Soo JUNG
;
Ju Ock KIM
;
Sun Young KIM
Author Information
- Publication Type:Original Article
- Keywords: Belotecan; Extensive disease; Small cell lung carcinoma; Cisplatin; First-line
- MeSH: Anemia; Brain; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Therapy, Combination; Humans; Neoplasm Metastasis; Neutropenia; Small Cell Lung Carcinoma; Thrombocytopenia
- From:Journal of Lung Cancer 2010;9(1):15-19
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Belotecan (Camtobell(R); Chong Keun Dang Co., Seoul, Korea) is a new camptothecin analog that inhibits topoisomerase I. We evaluated the efficacy and toxicity of belotecan combined with cisplatin in patients with previously untreated extensive-disease small cell lung cancer (ED-SCLC) and who were without evidence of brain metastases. MATERIALS AND METHODS: Twenty patients with previously untreated ED-SCLC were treated with belotecan (0.5 mg/m2/day) on days 1~4 and with cisplatin (60 mg/m2/day) on day 1 of a 3-week cycle. RESULTS: Of the 19 assessable patients, 16 had an objective tumor response, including two complete responses, for an overall response rate of 84.2%. Toxicity was evaluated in all 20 patients who received a total of 106 cycles (median cycles/patient, 5.5; range, 1~9). The major grade 3/4 hematologic toxicities were neutropenia (67.9% of cycles), anemia (19.8% of cycles) and thrombocytopenia (33.9% of cycles). No grade 3/4 non-hematologic toxicities were observed. No treatment-related deaths occurred. The median progression-free and overall survivals were 7.06 months (95% confidence interval [CI], 3.98~10.14 months) and 9.96 months (95% CI, 6.12~13.80 months), respectively. CONCLUSION: Combination chemotherapy with belotecan plus cisplatin is an effective treatment for ED-SCLC with acceptable hematologic and non-hematologic toxicities.
